Anna is from Cambridge, England and recently finished her undergraduate degree, where she specialised in Biological Anthropology. She has an interest in medicine and enjoys writing. In her spare time she likes to cook, hike, and hang out with cats.

    Four New Drugs Accepted by the Scottish Medicines Consortium
    <a href="https://pixabay.com/users/qimono/">qimono</a> / Pixabay

    Four New Drugs Accepted by the Scottish Medicines Consortium

      The Scottish Medicines Consortium, a committee that advises NHS Scotland on what medicines they should provide, has accepted four new drugs for use. These are gemtuzumab ozogamicin for acute…

    Continue Reading
    A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe
    <a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

    A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe

    According to a recent press release from Bluebird Bio, the European Medicines Agency has accepted and will review their marketing authorization application (MAA) for the investigational gene therapy LentiGlobin™ as…

    Continue Reading
    Plans for a Clinical Trial of Coversin in Patients With Thrombotic Microangiopathies Have Been Announced
    <a href="https://pixabay.com/users/mohamed_hassan/">mohamed_hassan</a> / Pixabay

    Plans for a Clinical Trial of Coversin in Patients With Thrombotic Microangiopathies Have Been Announced

    A drug called Coversin is being investigated as a potential treatment for four orphan diseases: bullous pemphigoid (BP), atypical keratoconjunctivitis (AKC), thrombotic microangiopathies, and paroxysmal nocturnal hemoglobinuria (PNH). Recently, new…

    Continue Reading
    Close Menu